Pharmacoeconomic analysis of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs. 5-FU/cisplatin (FP) regimens in an Italian setting

被引：3
|
作者：
Garrison, L. P.
Cirrincione, A.
Giuliani, G.
机构：
[1] Univ Washington, Seattle, WA USA
[2] F Hoffman La Roche ltd, Basel, Switzerland
[3] Roche SpA, Milan, Italy
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68925-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A127 / A127
页数：1
相关论文
共 50 条
  • [1] Economic evaluation of the cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs. 5-FU/cisplatin (FP) regimens in an Italian setting
    Giuliani, G.
    Falcone, A.
    Garrison, L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] COST MINIMIZATION ANALYSIS (CMA) OF CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN ADVANCED GASTRIC CANCER (AGC) TREATMENT IN THE ROMANIAN SETTING
    Curescu, S.
    Stanculeanu, D. L.
    Croitoru, A.
    Radu, C. P.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A453 - A453
  • [3] COST MINIMIZATION ANALYSIS OF ADVANCED GASTRIC CANCER TREATMENT WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN POLISH SETTING
    Kawalec, P.
    Szawlowski, A.
    Federowicz, I
    Szkultecka-Debek, M.
    Russel-Szymczyk, M.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A473 - A473
  • [4] Cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin vs. 5-FU/cisplatin regimens: An economic evaluation from an Italian perspective
    Giuliani, G.
    Falcone, A.
    Cirrincione, A.
    Garrison, L.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 265 - 265
  • [5] Similar safety results of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) from a phase III trial in patients (pts) with previously untreated advanced gastric cancer (AGC)
    Kang, Y. K.
    Kang, W. K.
    Shin, D. B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M. P.
    Suarez, T.
    Santamaria, J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 205 - 205
  • [6] Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results
    Kang, Y.
    Kang, W.
    Shin, D.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M.
    Suarez, T.
    Santamaria, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 19 - 19
  • [7] AN ECONOMIC EVALUATION OF CAPECITABINE/CISPLATIN PLUS 5-FU/CISPLATIN REGIMENS IN TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN
    Darba, J.
    Restovic, G.
    Ramirez de Arellano, A.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A466 - A466
  • [8] Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results.
    Kang, Y.
    Kang, W. K.
    Shin, D. B.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Salas, M. P.
    Suarez, T.
    Santamaria, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 183S - 183S
  • [9] Economic assessment of capecitabine/cisplatin versus 5-FU/cisplatin regimens in adjuvant treatment of advanced gastric cancer in Spain
    Safont, M.
    Darba, J.
    Restovic, G.
    Sastre, J.
    Bellmunt Molins, J.
    Gomez, M. A.
    Salgado, M.
    Vila, C.
    Ramirez De Arellano, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] ECONOMIC ASSESSMENT OF CAPECITABINE/CISPLATIN VERSUS 5-FU/CISPLATIN REGIMENS IN ADJUVANT TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN
    Darba, J.
    Restovic, G.
    Ramirez de Arellano, A.
    Safont, M.
    Sastre, J.
    Bellmunt, J.
    Gomez, M.
    Salgado, M.
    Vila, C.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 184 - 184
12345